Expanded Access (EA) may be considered for patients who have exhausted their treatment options and are not eligible for, or able to participate in, a clinical trial.
EA - also known as compassionate use, named-patient use, or single-patient access - provides some patients who have serious or life-threatening diseases or conditions with access to investigational treatments not approved by the U.S. Food and Drug Administration (FDA). The Reagan-Udall Foundation’s Expanded Access Navigator provides physicians, patients, and caregivers with guidance on EA and related topics. Scroll down to begin using the Navigator.
Select the step-by-step guide best matching your needs.